Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  de Cassan, Simone C ^a   Rushdi Shakri, A ^b   Llewellyn, David ^a   Elias, Sean C ^a   Cho, Jee Sun ^c,d   Goodman, Anna L ^a   Jin, Jing ^a   Douglas, Alexander D ^a   Suwanarusk, Rossarin ^c,d   Nosten, François H ^e   Rénia, Laurent ^c,d   Russell, Bruce ^c   Chitnis, Chetan E ^b,f   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

^e SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^f INSTITUT PASTEUR   (France)

Author keywords

Adenovirus; Blood stage; Duffy binding protein; Malaria; MVA; Plasmodium vivax; Poxvirus; Vaccine

Indexed keywords

DUFFY BINDING PROTEIN; GAMMA INTERFERON; MALARIA VACCINE; PLASMODIUM VIVAX DUFFY BINDING PROTEIN REGION 2 VACCINE; THYMIDINE KINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL INVASION; CHIMPANZEE ADENOVIRUS SEROTYPE 63; CONTROLLED STUDY; DNA VIRUS; DRUG TARGETING; ENZYME INHIBITION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; HUMAN ADENOVIRUS 5; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM VIVAX MALARIA; PROTEIN BINDING; RABBIT; RECOMBINANT DNA TECHNOLOGY; RECURRENT DISEASE; SEROTYPE; ULTRAVIOLET SPECTROPHOTOMETRY; VACCINATION;

EID: 84935104513     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00348     Document Type: Article

References (87)

1. Antrobus, R.D., Coughlan, L., Berthoud, T.K., Dicks, M.D., Hill, A.V., Lambe, T., and Gilbert, S.C. (2014). Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Mol Ther 22, 668-674.
2. Arevalo-Herrera, M., Chitnis, C., and Herrera, S. (2010). Current status of Plasmodium vivax vaccine. Hum Vaccin 6, 124-132.
3. Baird, J.K. (2013). Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 26, 36-57.
4. Batchelor, J.D., Malpede, B.M., Omattage, N.S., Dekoster, G.T., Henzler-Wildman, K.A., and Tolia, N.H. (2014). Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLoS Pathog 10, e1003869.
5. Bennett, J.W., Pybus, B.S., Yadava, A., Tosh, D., Sousa, J.C., Mccarthy, W.F., Deye, G., Melendez, V., and Ockenhouse, C.F. (2013). Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria. N Engl J Med 369, 1381-1382.
6. Biswas, S., Choudhary, P., Elias, S.C., Miura, K., Milne, K.H., De Cassan, S.C., Collins, K.A., Halstead, F.D., Bliss, C.M., Ewer, K.J., Osier, F.H., Hodgson, S.H., Duncan, C.J., O'hara, G.A., Long, C.A., Hill, A.V., and Draper, S.J. (2014). Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. PLoS One 9, e107903.
7. Biswas, S., Dicks, M.D., Long, C.A., Remarque, E.J., Siani, L., Colloca, S., Cottingham, M.G., Holder, A.A., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2011). Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS One 6, e20977.
8. Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E.J., Black, A., Bridgeman, A., Rosario, M., Hill, A.V., Berrie, E., Moyle, S., Frahm, N., Cox, J., Colloca, S., Nicosia, A., Gilmour, J., Mcmichael, A.J., Dorrell, L., and Hanke, T. (2014). Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Mol Ther 22, 464-475.
9. Bouharoun-Tayoun, H., and Druilhe, P. (1992). Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60, 1473-1481.
10. Boyle, M.J., Reiling, L., Feng, G., Langer, C., Osier, F.H., Aspeling-Jones, H., Cheng, Y.S., Stubbs, J., Tetteh, K.K., Conway, D.J., Mccarthy, J.S., Muller, I., Marsh, K., Anders, R.F., and Beeson, J.G. (2015). Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria. Immunity 42, 580-590.
11. Capone, S., D'alise, A.M., Ammendola, V., Colloca, S., Cortese, R., Nicosia, A., and Folgori, A. (2013). Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 12, 379-393.
12. Ceravolo, I.P., Sanchez, B.A., Sousa, T.N., Guerra, B.M., Soares, I.S., Braga, E.M., Mchenry, A.M., Adams, J.H., Brito, C.F., and Carvalho, L.H. (2009). Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol 156, 502-510.
13. Chitnis, C.E., and Miller, L.H. (1994). Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 180, 497-506.
14. Chitnis, C.E., and Sharma, A. (2008). Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 24, 29-34.
15. Cole-Tobian, J.L., Michon, P., Biasor, M., Richards, J.S., Beeson, J.G., Mueller, I., and King, C.L. (2009). Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun 77, 4009-4017.
16. Coler, R.N., Carter, D., Friede, M., and Reed, S.G. (2009). Ad juvants for malaria vaccines. Parasite Immunol 31, 520-528.
17. Colloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M.L., Ambrosio, M., Sparacino, A., Bartiromo, M., Meola, A., Smith, K., Kurioka, A., O'hara, G.A., Ewer, K.J., Anagnostou, N., Bliss, C., Hill, A.V., Traboni, C., Klenerman, P., Cortese, R., and Nicosia, A. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4, 115ra112.
18. Cox, R.J., Pedersen, G., Madhun, A.S., Svindland, S., Saevik, M., Breakwell, L., Hoschler, K., Willemsen, M., Campitelli, L., Nostbakken, J.K., Weverling, G.J., Klap, J., Mccullough, K.C., Zambon, M., Kompier, R., and Sjursen, H. (2011). Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29, 8049-8059.
19. Crotty, S. (2012). The 1-1-1 fallacy. Immunol Rev 247, 133-142.
20. De Barra, E., Hodgson, S.H., Ewer, K.J., Bliss, C.M., Hennigan, K., Collins, A., Berrie, E., Lawrie, A.M., Gilbert, S.C., Nicosia, A., Mcconkey, S.J., and Hill, A.V. (2014). A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One 9, e115161.
21. De Cassan, S.C., and Draper, S.J. (2013). Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 12, 365-378.
22. De Cassan, S.C., Forbes, E.K., Douglas, A.D., Milicic, A., Singh, B., Gupta, P., Chauhan, V.S., Chitnis, C.E., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2011). The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187, 2602-2616.
23. Devi, Y.S., Mukherjee, P., Yazdani, S.S., Shakri, A.R., Mazumdar, S., Pandey, S., Chitnis, C.E., and Chauhan, V.S. (2007). Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. Vaccine 25, 5166-5174.
24. Dicks, M.D., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V., and Cottingham, M.G. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7, e40385.
25. Douglas, A.D., Baldeviano, G.C., Lucas, C.M., Lugo-Roman, L.A., Crosnier, C., Bartholdson, S.J., Diouf, A., Miura, K., Lambert, L.E., Ventocilla, J.A., Leiva, K.P., Milne, K.H., Illingworth, J.J., Spencer, A.J., Hjerrild, K.A., Alanine, D.G., Turner, A.V., Moorhead, J.T., Edgel, K.A., Wu, Y., Long, C.A., Wright, G.J., Lescano, A.G., and Draper, S.J. (2015). A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host Microbe 17, 130-139.
26. Douglas, A.D., De Cassan, S.C., Dicks, M.D., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2010). Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167-7178.
27. Douglas, A.D., Williams, A.R., Illingworth, J.J., Kamuyu, G., Biswas, S., Goodman, A.L., Wyllie, D.H., Crosnier, C., Miura, K., Wright, G.J., Long, C.A., Osier, F.H., Marsh, K., Turner, A.V., Hill, A.V., and Draper, S.J. (2011). The blood-stage malaria antigen PfRH5 is susceptible to vaccine inducible cross-strain neutralizing antibody. Nat Commun 2, 601.
28. Douglas, A.D., Williams, A.R., Knuepfer, E., Illingworth, J.J., Furze, J.M., Crosnier, C., Choudhary, P., Bustamante, L.Y., Zakutansky, S.E., Awuah, D.K., Alanine, D.G., Theron, M., Worth, A., Shimkets, R., Rayner, J.C., Holder, A.A., Wright, G.J., and Draper, S.J. (2014). Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5. J Immunol 192, 245-258.
29. Draper, S.J., Biswas, S., Spencer, A.J., Remarque, E.J., Capone, S., Naddeo, M., Dicks, M.D.J., Faber, B.W., De Cassan, S.C., Folgori, A., Nicosia, A., Gilbert, S.C., and Hill, A.V.S. (2010). Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185, 7583-7595.
30. Draper, S.J., and Heeney, J.L. (2010). Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8, 62-73.
31. Draper, S.J., Moore, A.C., Goodman, A.L., Long, C.A., Holder, A.A., Gilbert, S.C., Hill, F., and Hill, A.V. (2008). Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14, 819-821.
32. Ewer, K.J., O'hara, G.A., Duncan, C.J., Collins, K.A., Sheehy, S.H., Reyes-Sandoval, A., Goodman, A.L., Edwards, N.J., Elias, S.C., Halstead, F.D., Longley, R.J., Rowland, R., Poulton, I.D., Draper, S.J., Blagborough, A.M., Berrie, E., Moyle, S., Williams, N., Siani, L., Folgori, A., Colloca, S., Sinden, R.E., Lawrie, A.M., Cortese, R., Gilbert, S.C., Nicosia, A., and Hill, A.V. (2013). Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4, 2836.
33. Forbes, E.K., Biswas, S., Collins, K.A., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2011). Combining Liver and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. J Immunol 187, 3738-3750.
34. Francica, J.R., Sheng, Z., Zhang, Z., Nishimura, Y., Shingai, M., Ramesh, A., Keele, B.F., Schmidt, S.D., Flynn, B.J., Darko, S., Lynch, R.M., Yamamoto, T., Matus-Nicodemos, R., Wolinsky, D., Nason, M., Valiante, N.M., Malyala, P., De Gregorio, E., Barnett, S.W., Singh, M., O'hagan, D.T., Koup, R.A., Mascola, J.R., Martin, M.A., Kepler, T.B., Douek, D.C., Shapiro, L., and Seder, R.A. (2015). Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nat Commun 6, 6565.
35. Galinski, M.R., and Barnwell, J.W. (2008). Plasmodium vivax: who cares? Malar J 7 Suppl 1, S9.
36. Gething, P.W., Elyazar, I.R., Moyes, C.L., Smith, D.L., Battle, K.E., Guerra, C.A., Patil, A.P., Tatem, A.J., Howes, R.E., Myers, M.F., George, D.B., Horby, P., Wertheim, H.F., Price, R.N., Mueller, I., Baird, J.K., and Hay, S.I. (2012). A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 6, e1814.
37. Goodman, A.L., Blagborough, A.M., Biswas, S., Wu, Y., Hill, A.V., Sinden, R.E., and Draper, S.J. (2011). A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. PLoS One 6, e29428.
38. Goodman, A.L., and Draper, S.J. (2010). Blood-stage malaria vaccines-recent progress and future challenges. Ann Trop Med Parasitol 104, 189-211.
39. Goodman, A.L., Epp, C., Moss, D., Holder, A.A., Wilson, J.M., Gao, G.P., Long, C.A., Remarque, E.J., Thomas, A.W., Ammendola, V., Colloca, S., Dicks, M.D., Biswas, S., Seibel, D., Van Duivenvoorde, L.M., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2010). New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 78, 4601-4612.
40. Goodman, A.L., Forbes, E.K., Williams, A.R., Douglas, A.D., De Cassan, S.C., Bauza, K., Biswas, S., Dicks, M.D., Llewellyn, D., Moore, A.C., Janse, C.J., Franke-Fayard, B.M., Gilbert, S.C., Hill, A.V., Pleass, R.J., and Draper, S.J. (2013). The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Sci Rep 3, 1706.
41. Grimberg, B.T., Udomsangpetch, R., Xainli, J., Mchenry, A., Panichakul, T., Sattabongkot, J., Cui, L., Bockarie, M., Chitnis, C., Adams, J., Zimmerman, P.A., and King, C.L. (2007). Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 4, e337.
42. Harvey, K.L., Gilson, P.R., and Crabb, B.S. (2012). A model for the progression of receptor-ligand interactions during erythrocyte invasion by Plasmodium falciparum. Int J Parasitol 42, 567-573.
43. Herrera, S., Fernandez, O.L., Vera, O., Cardenas, W., Ramirez, O., Palacios, R., Chen-Mok, M., Corradin, G., and Arevalo-Herrera, M. (2011a). Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg 84, 12-20.
44. Herrera, S., Solarte, Y., Jordan-Villegas, A., Echavarria, J.F., Rocha, L., Palacios, R., Ramirez, O., Velez, J.D., Epstein, J.E., Richie, T.L., and Arevalo-Herrera, M. (2011b). Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg 84, 4-11.
45. Hill, A.V. (2011). Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 366, 2806-2814.
46. Hodgson, S.H., Choudhary, P., Elias, S.C., Milne, K.H., Rampling, T.W., Biswas, S., Poulton, I.D., Miura, K., Douglas, A.D., Alanine, D.G., Illingworth, J.J., De Cassan, S.C., Zhu, D., Nicosia, A., Long, C.A., Moyle, S., Berrie, E., Lawrie, A.M., Wu, Y., Ellis, R.D., Hill, A.V., and Draper, S.J. (2014). Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. Mol Ther 22, 2142-2154.
47. Howes, R.E., Patil, A.P., Piel, F.B., Nyangiri, O.A., Kabaria, C.W., Gething, P.W., Zimmerman, P.A., Barnadas, C., Beall, C.M., Gebremedhin, A., Menard, D., Williams, T.N., Weatherall, D.J., and Hay, S.I. (2011). The global distribution of the Duffy blood group. Nat Commun 2, 266.
48. Kapelski, S., Klockenbring, T., Fischer, R., Barth, S., and Fendel, R. (2014). Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J Leukoc Biol.
49. King, C.L., Michon, P., Shakri, A.R., Marcotty, A., Stanisic, D., Zimmerman, P.A., Cole-Tobian, J.L., Mueller, I., and Chitnis, C.E. (2008). Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A 105, 8363-8368.
50. Malkin, E.M., Durbin, A.P., Diemert, D.J., Sattabongkot, J., Wu, Y., Miura, K., Long, C.A., Lambert, L., Miles, A.P., Wang, J., Stowers, A., Miller, L.H., and Saul, A. (2005). Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23, 3131-3138.
51. Malleret, B., Li, A., Zhang, R., Tan, K.S., Suwanarusk, R., Claser, C., Cho, J.S., Koh, E.G., Chu, C.S., Pukrittayakamee, S., Ng, M.L., Ginhoux, F., Ng, L.G., Lim, C.T., Nosten, F., Snounou, G., Renia, L., and Russell, B. (2015). Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes. Blood 125, 1314-1324.
52. Menard, D., Barnadas, C., Bouchier, C., Henry-Halldin, C., Gray, L.R., Ratsimbasoa, A., Thonier, V., Carod, J.F., Domarle, O., Colin, Y., Bertrand, O., Picot, J., King, C.L., Grimberg, B.T., Mercereau-Puijalon, O., and Zimmerman, P.A. (2010). Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 107, 5967-5971.
53. Menard, D., Chan, E.R., Benedet, C., Ratsimbasoa, A., Kim, S., Chim, P., Do, C., Witkowski, B., Durand, R., Thellier, M., Severini, C., Legrand, E., Musset, L., Nour, B.Y., Mercereau-Puijalon, O., Serre, D., and Zimmerman, P.A. (2013). Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains. PLoS Negl Trop Dis 7, e2489.
54. Miller, L.H., Mason, S.J., Clyde, D.F., and Mcginniss, M.H. (1976). The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295, 302-304.
55. Miura, K., Orcutt, A.C., Muratova, O.V., Miller, L.H., Saul, A., and Long, C.A. (2008). Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193-200.
56. Miura, K., Zhou, H., Diouf, A., Moretz, S.E., Fay, M.P., Miller, L.H., Martin, L.B., Pierce, M.A., Ellis, R.D., Mullen, G.E., and Long, C.A. (2009). Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16, 963-968.
57. Moorthy, V.S., Newman, R.D., and Okwo-Bele, J.M. (2013). Malaria vaccine technology roadmap. Lancet 382, 1700-1701.
58. Moreno, A., Caro-Aguilar, I., Yazdani, S.S., Shakri, A.R., Lapp, S., Strobert, E., Mcclure, H., Chitnis, C.E., and Galinski, M.R. (2008). Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques. Vaccine 26, 4338-4344.
59. Ndiaye, B.P., Thienemann, F., Ota, M., Landry, B.S., Camara, M., Dieye, S., Dieye, T.N., Esmail, H., Goliath, R., Huygen, K., January, V., Ndiaye, I., Oni, T., Raine, M., Romano, M., Satti, I., Sutton, S., Thiam, A., Wilkinson, K.A., Mboup, S., Wilkinson, R.J., and Mcshane, H. (2015). Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 3, 190-200.
60. Ntumngia, F.B., Schloegel, J., Barnes, S.J., Mchenry, A.M., Singh, S., King, C.L., and Adams, J.H. (2012). Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies. Infect Immun 80, 1203-1208.
61. O'hara, G.A., Duncan, C.J., Ewer, K.J., Collins, K.A., Elias, S.C., Halstead, F.D., Goodman, A.L., Edwards, N.J., Reyes-Sandoval, A., Bird, P., Rowland, R., Sheehy, S.H., Poulton, I.D., Hutchings, C., Todryk, S., Andrews, L., Folgori, A., Berrie, E., Moyle, S., Nicosia, A., Colloca, S., Cortese, R., Siani, L., Lawrie, A.M., Gilbert, S.C., and Hill, A.V. (2012). Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis 205, 772-781.
62. Osier, F.H., Feng, G., Boyle, M.J., Langer, C., Zhou, J., Richards, J.S., Mccallum, F.J., Reiling, L., Jaworowski, A., Anders, R.F., Marsh, K., and Beeson, J.G. (2014). Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 12, 108.
63. Quinn, K.M., Da Costa, A., Yamamoto, A., Berry, D., Lindsay, R.W., Darrah, P.A., Wang, L., Cheng, C., Kong, W.P., Gall, J.G., Nicosia, A., Folgori, A., Colloca, S., Cortese, R., Gostick, E., Price, D.A., Gomez, C.E., Esteban, M., Wyatt, L.S., Moss, B., Morgan, C., Roederer, M., Bailer, R.T., Nabel, G.J., Koup, R.A., and Seder, R.A. (2013). Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190, 2720-2735.
64. Rampling, T., Ewer, K., Bowyer, G., Wright, D., Imoukhuede, E.B., Payne, R., Hartnell, F., Gibani, M., Bliss, C., Minhinnick, A., Wilkie, M., Venkatraman, N., Poulton, I., Lella, N., Roberts, R., Sierra-Davidson, K., Krahling, V., Berrie, E., Roman, F., De Ryck, I., Nicosia, A., Sullivan, N.J., Stanley, D.A., Ledgerwood, J.E., Schwartz, R.M., Siani, L., Colloca, S., Folgori, A., Di Marco, S., Cortese, R., Becker, S., Graham, B.S., Koup, R.A., Levine, M.M., Moorthy, V., Pollard, A.J., Draper, S.J., Ballou, W.R., Lawrie, A., Gilbert, S.C., and Hill, A.V. (2015). A Monovalent Chimpanzee Adenovirus Ebola Vaccine-Preliminary Report. N Engl J Med.
65. Reyes-Sandoval, A., Berthoud, T., Alder, N., Siani, L., Gilbert, S.C., Nicosia, A., Colloca, S., Cortese, R., and Hill, A.V. (2010). Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T cell responses. Infect Immun 78, 145-153.
66. Roestenberg, M., Remarque, E., De Jonge, E., Hermsen, R., Blythman, H., Leroy, O., Imoukhuede, E., Jepsen, S., Ofori-Anyinam, O., Faber, B., Kocken, C.H., Arnold, M., Walraven, V., Teelen, K., Roeffen, W., De Mast, Q., Ballou, W.R., Cohen, J., Dubois, M.C., Ascarateil, S., Van Der Ven, A., Thomas, A., and Sauerwein, R. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 3, e3960.
67. Russell, B., Suwanarusk, R., Borlon, C., Costa, F.T., Chu, C.S., Rijken, M.J., Sriprawat, K., Warter, L., Koh, E.G., Malleret, B., Colin, Y., Bertrand, O., Adams, J.H., D'alessandro, U., Snounou, G., Nosten, F., and Renia, L. (2011). A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood 118, e74-81.
68. Sampath, S., Carrico, C., Janes, J., Gurumoorthy, S., Gibson, C., Melcher, M., Chitnis, C.E., Wang, R., Schief, W.R., and Smith, J.D. (2013). Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development. PLoS Pathog 9, e1003420.
69. Shakri, A.R., Rizvi, M.M., and Chitnis, C.E. (2012). Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II. J Immunoassay Immunochem 33, 403-413.
70. Sheehy, S.H., Duncan, C.J., Elias, S.C., Biswas, S., Collins, K.A., O'hara, G.A., Halstead, F.D., Ewer, K.J., Mahungu, T., Spencer, A.J., Miura, K., Poulton, I.D., Dicks, M.D., Edwards, N.J., Berrie, E., Moyle, S., Colloca, S., Cortese, R., Gantlett, K., Long, C.A., Lawrie, A.M., Gilbert, S.C., Doherty, T., Nicosia, A., Hill, A.V., and Draper, S.J. (2012a). Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS One 7, e31208.
71. Sheehy, S.H., Duncan, C.J., Elias, S.C., Choudhary, P., Biswas, S., Halstead, F.D., Collins, K.A., Edwards, N.J., Douglas, A.D., Anagnostou, N.A., Ewer, K.J., Havelock, T., Mahungu, T., Bliss, C.M., Miura, K., Poulton, I.D., Lillie, P.J., Antrobus, R.D., Berrie, E., Moyle, S., Gantlett, K., Colloca, S., Cortese, R., Long, C.A., Sinden, R.E., Gilbert, S.C., Lawrie, A.M., Doherty, T., Faust, S.N., Nicosia, A., Hill, A.V., and Draper, S.J. (2012b). ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Mol Ther 20, 2355-2368.
72. Sheehy, S.H., Duncan, C.J., Elias, S.C., Collins, K.A., Ewer, K.J., Spencer, A.J., Williams, A.R., Halstead, F.D., Moretz, S.E., Miura, K., Epp, C., Dicks, M., Poulton, I.D., Lawrie, A.M., Berrie, E., Moyle, S., Long, C.A., Colloca, S., Cortese, R., Gilbert, S.C., Nicosia, A., Hill, A.V., and Draper, S.J. (2011). Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Mol Ther 19, 2269-2276.
73. Siddiqui, A.A., Xainli, J., Schloegel, J., Carias, L., Ntumngia, F., Shoham, M., Casey, J.L., Foley, M., Adams, J.H., and King, C.L. (2012). Fine specificity of Plasmodium vivax Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes. Infect Immun 80, 2920-2928.
74. Singh, A.P., Ozwara, H., Kocken, C.H., Puri, S.K., Thomas, A.W., and Chitnis, C.E. (2005). Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion. Mol Microbiol 55, 1925-1934.
75. Singh, A.P., Puri, S.K., and Chitnis, C.E. (2002). Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol 121, 21-31.
76. Sridhar, S., Reyes-Sandoval, A., Draper, S.J., Moore, A.C., Gilbert, S.C., Gao, G.P., Wilson, J.M., and Hill, A.V. (2008). Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 82, 3822-3833.
77. Stewart, V.A., Mcgrath, S.M., Dubois, P.M., Pau, M.G., Mettens, P., Shott, J., Cobb, M., Burge, J.R., Larson, D., Ware, L.A., Demoitie, M.A., Weverling, G.J., Bayat, B., Custers, J.H., Dubois, M.C., Cohen, J., Goudsmit, J., and Heppner, D.G., Jr. (2007). Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75, 2283-2290.
78. Swadling, L., Capone, S., Antrobus, R.D., Brown, A., Richardson, R., Newell, E.W., Halliday, J., Kelly, C., Bowen, D., Fergusson, J., Kurioka, A., Ammendola, V., Del Sorbo, M., Grazioli, F., Esposito, M.L., Siani, L., Traboni, C., Hill, A., Colloca, S., Davis, M., Nicosia, A., Cortese, R., Folgori, A., Klenerman, P., and Barnes, E. (2014). A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6, 261ra153.
79. Tham, W.H., Healer, J., and Cowman, A.F. (2012). Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol 28, 23-30.
80. Tran, T.M., Oliveira-Ferreira, J., Moreno, A., Santos, F., Yazdani, S.S., Chitnis, C.E., Altman, J.D., Meyer, E.V., Barnwell, J.W., and Galinski, M.R. (2005). Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am J Trop Med Hyg 73, 244-255.
81. Vicentin, E.C., Francoso, K.S., Rocha, M.V., Iourtov, D., Dos Santos, F.L., Kubrusly, F.S., Sakauchi, M.A., Raw, I., Nosten, F., Renia, L., Rodrigues, M.M., Russell, B., and Soares, I.S. (2014). Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast. Infect Immun 82, 1296-1307.
82. Vinner, L., Therrien, D., Wee, E., Laursen, I., Hanke, T., Corbet, S.L., and Fomsgaard, A. (2006). Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. Apmis 114, 690-699.
83. Wiley, S.R., Raman, V.S., Desbien, A., Bailor, H.R., Bhardwaj, R., Shakri, A.R., Reed, S.G., Chitnis, C.E., and Carter, D. (2011). Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 3, 93ra69.
84. Wu, Y., Ellis, R.D., Shaffer, D., Fontes, E., Malkin, E.M., Mahanty, S., Fay, M.P., Narum, D., Rausch, K., Miles, A.P., Aebig, J., Orcutt, A., Muratova, O., Song, G., Lambert, L., Zhu, D., Miura, K., Long, C., Saul, A., Miller, L.H., and Durbin, A.P. (2008). Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3, e2636.
85. Xainli, J., Baisor, M., Kastens, W., Bockarie, M., Adams, J.H., and King, C.L. (2002). Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol 169, 3200-3207.
86. Yazdani, S.S., Shakri, A.R., Mukherjee, P., Baniwal, S.K., and Chitnis, C.E. (2004). Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22, 3727-3737.
87. Yazdani, S.S., Shakri, A.R., Pattnaik, P., Rizvi, M.M., and Chitnis, C.E. (2006). Improvement in yield and purity of a recombinant malaria vaccine candidate based on the receptor-binding domain of Plasmodium vivax Duffy binding protein by codon optimization. Biotechnol Lett 28, 1109-1114.